Souhaitez-vous accéder aux communiqués récents ?

Key data readouts for the company’s late-stage, potentially registrational trials of nemvaleukin are expected in late Q1/early Q2 2025 for platinum-resistant ovarian cancer and Q2 2025 for mucosal...

Barinthus Bio Announces Strategic Pipeline Prioritization Following Positive Interim Data from VTP-300 in Chronic Hepatitis B Virus Infections

Azuria Announces Acquisition of Infrastructure Services Group LLC and Subsidiaries

AUROBAC THERAPEUTICS to advance ATX101 in septic shock, and multiple preclinical and discovery programs targeting Gram-negative pathogens. Lyon (France), June 3, 2024 AUROBAC THERAPEUTICS, a...

ARTISTRY-3 trial is being conducted to evaluate less frequent dosing of nemvaleukin alfa, Mural’s late-stage lead candidate Nemvaleukin demonstrated pharmacodynamic proof of mechanism in ARTISTRY-3...

Mural Oncology reiterates cash runway projection into 4Q 2025, with sufficient capital to fund key clinical readouts.

Aegion Corporation today announced its official rebrand to Azuria Water Solutions, the leading provider of technology-enabled products and services.

Human Pharma sales up 10.3%* to EUR 20.8 bn, driven by JARDIANCE® and OFEV®Animal Health sales up 6.9 %* to EUR 4.7 bn, fueled by new product launchesR&D expenditures increase by 14.2% to EUR 5.8...

Tevogen’s Chief Scientific Officer explains the company’s oncology pipeline strategy as it relates to harnessing Cytotoxic T Lymphocytes to target cancers.

Mural Oncology, a clinical-stage immuno-oncology company, shared pre-clinical data from its Interleukin-18 (IL-18) and IL-12 programs at AACR today.